FDA to authorize plasma treatment over scientists’ objections


The Food and Drug Administration will issue an emergency authorization for blood plasma as a coronavirus treatment, according to three administration officials.

The agency held off on the decision over concerns from government scientists that evidence for the treatment’s effectiveness is thin – prompting President Donald Trump to accuse the FDA of slow-walking the therapy to harm his reelection chances.

Trump will announce the emergency authorization during a Sunday evening press conference with HHS Secretary Alex Azar and FDA Commissioner Stephen Hahn.